Similarly, in the adjuvant treatment of early breast cancer, oral SERDs are being studied against AIs or physicians’ choice as in the Lidera Breast Cancer Study [91] (giredestrant) or tamoxifen as in AMEERA-6 [92] (amcenestrant) in HR + /HER2 − stages I–II early breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.